BiotechTube
Home/Pipeline/Kymriah® (tisagenlecleucel)

Kymriah® (tisagenlecleucel)

B-cell Malignancies

ApprovedActiveN/A

Key Facts

Indication
B-cell Malignancies
Phase
Approved
Status
Active
Company
Novartis

About Novartis

Novartis is a global pharmaceutical leader with a mission to reimagine medicine to improve and extend lives. With a market cap of $290.10B, it operates across 118 countries, reaching over 300 million patients annually. Its strategy focuses on delivering high-value medicines for society's greatest disease burdens through technology leadership in R&D and novel access approaches, powered by a diversified portfolio across oncology, cardiovascular, immunology, neuroscience, and rare diseases.

View full company profile

Therapeutic Areas

Cardiovascular, Renal and MetabolicImmunologyNeuroscienceOncology

Other B-cell Malignancies Drugs

DrugCompanyPhase
BI-1607BioInvent InternationalPreclinical/Phase 1
BAFFR Allo CAR-NK CellsPeproMene BioPre-clinical
IKS03Iksuda TherapeuticsClinical
TNB-486Ancora BioPhase 1
docirbrutinib (AS-1763)Carna BiosciencesPhase 1b
P-CD19CD20-ALLO1Poseida TherapeuticsPhase 1
KITE-363Gilead SciencesPhase 1/2
HSK29116Haisco Pharmaceutical GroupPhase I/II
TG-1701TG TherapeuticsPhase 1
TG-1801TG TherapeuticsPhase 1
REC-3565Recursion PharmaceuticalsPhase 1
Plamotamab (XmAb®13676)XencorPhase 2